Canadian Medical Association Journal eCMAJ Home  

Public Health
Anthrax: walking the fine line between precaution and panic
CMAJ 2001;165(11):


Background and epidemiology: With this issue, CMAJ’s Public Health page is taking its third look at anthrax in as many years.1,2 With each visit, the essence of the disease, caused by Bacillus anthracis, does not change. Anthrax in Canada remains primarily a disease of herbivores, particularly bison and deer. Bacillus anthracis spores lie dormant in contaminated soil until ingested or inhaled by grazing animals; they germinate in the animals and release toxins that cause massive edema, hemorrhagic lymphadenitis and death from shock. The spores pose little threat to humans unless exceptional circumstances allow exposure and transmission of sufficient doses by inhalation, inoculation through an open wound or ingestion. Direct person-to-person spread of anthrax has not been documented. Human cases in Canada have been virtually eliminated thanks to livestock vaccination and industrial sanitary programs, restrictions on imported wool, hides and other products, and the proper disposal of infected animals; Canada’s last reported case of anthrax, a sporadic incident of dermal exposure, occurred in 1990.3

Since Sept. 11, 2001, exceptional circumstances have arisen in the US because of bioterrorist activity. By Oct. 22, a series of targeted letters, aimed primarily at members of the American media, had resulted in 3 confirmed cases of inhalational anthrax (1 fatal) and 2 confirmed cases of cutaneous anthrax.4 To date, and despite many false alarms, including some outright pranks, there is no evidence of any intentional exposures or active cases of anthrax in Canada. As the prospect of bioterrorism becomes clearer over the next few months, physicians, patients and public health officials must help each other traverse the fine line between precaution and panic.

Clinical management: Inhalational anthrax results from the inspiration of 8000 to 50 000 spores of B. anthracis. The incubation period ranges from 1 to 7 days, but may be up to 60 days. It begins with a brief prodrome that resembles a viral respiratory illness, but rapidly deteriorates to dyspnea and hypoxia, with radiographic evidence of a widened mediastinum. Respiratory failure, shock and meningitis ensue; case-fatality estimates are extremely high despite supportive care and appropriate antibiotic treatment.4 (Intravenous ciprofloxacin is the first-line treatment; doxycycline is an acceptable alternative, although rare doxycycline-resistant strains of B. anthracis exist.5)

The skin lesion of cutaneous anthrax evolves from a papule through a vesicular stage, to a depressed black eschar. The incubation period is 1 to 12 days. The lesion is usually painless, but the patient often has fever, malaise, headache and regional lymphadenopathy. The case-fatality rate for cutaneous anthrax is 20% without and less than 1% with antibiotic treatment.4

Gastrointestinal anthrax presents with severe abdominal pain, fever and septicemia. The incubation period is 1 to 7 days after ingesting contaminated meat. Lower bowel inflammation causes nausea, loss of appetite, hematemesis and bloody diarrhea. There is also an oropharyngeal form that is characterized by lesions at the base of the tongue, dysphagia and lymphadenopathy. The case-fatality rate is 25% to 60%, and the effect of early antibiotic treatment is not established.4

Diagnosis is by culture from blood, skin lesions, respiratory secretions or serology; polymerase chain reaction (PCR) testing is available in some laboratories. Early antibiotic treatment can ameliorate the course of anthrax. Postexposure prophylaxis may be achieved in adults, including pregnant and immunocompromised persons, with oral ciprofloxacin (500 mg po bid) or doxycycline (100 mg po bid) for 60 days. Children should receive 10 to 15 mg/kg of ciprofloxacin po q12 hrs for 60 days (not to exceed 1 g per day). Doxycycline is a possible substitute, with doses varying according to the child’s age.4

Control and prevention: If a suspicious package is encountered — excessive postage, handwritten addresses, incorrect titles, misspellings of common words, stains or odours, and no return address — do not shake or open it. Cover it and any spillage, leave the room, close the door and section off the room. Wash your hands with soap and water. Phone the police and then make a list of all people present when the letter or package was recognized. Seal contaminated clothing in a plastic bag and take a shower with soap and water as soon as possible.6

Despite those warnings, the risk of anthrax exposure in Canada remains remote. Physicians are reminded that the inappropriate use of prophylactic antibiotics leads to increased antibiotic resistance among micro-organisms and may result in adverse effects such as Clostridium difficile colitis and allergic reactions. Stockpiling antibiotics and purchasing gas masks are discouraged. Anthrax vaccine is currently in short supply and not available to the general public or medical community. It requires 6 shots over 18 months. — Erica Weir, CMAJ


References

    1.   Hoey J. Anthrax. CMAJ 1998;158(5):633. [MEDLINE]
    2.   Weir E. Anthrax: of bison and bioterrorism. CMAJ 2000;163(5):608. [MEDLINE]
    3.   Wong C, Ng T. Cutaneous anthrax – British Columbia. Can Dis Wkly Rep 1991;17(6):31-3. [MEDLINE]
    4.   Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. Morb Mortal Wkly Rep 2001;50:889-93.
    5.   Cieslak TJ, Eitzen E. Clinical and epidemiologic principles of anthrax. Emerg Infect Dis 2000;6:1-7. Available: www.cdc.gov/ncidod/EID/vol5no4/cieslak.htm (accessed 2001 Oct 22).
    6.   Centers for Disease Control and Prevention. CDC Health Advisory: how to handle anthrax and other biological agent threats. Available: www.statesnews.org/domestic%20terrorism/CDC_anthrax.htm (accessed 2001 Oct 22).

 

 

Copyright 2001 Canadian Medical Association or its licensors